Table I.
Comparison of the clinical patient data with and without infection.
| Characteristics | Infected | Non-infected | P-value |
|---|---|---|---|
| Age, years | 21±11 | 19±8 | 0.52 |
| Gender, n (%) | |||
| Male | 3 (50.0) | 77 (64.7) | 0.75 |
| Female | 3 (50.0) | 42 (35.3) | |
| Tumor site, n (%) | |||
| Femur | 1 (16.7) | 62 (52.6) | 0.04 |
| Tibia | 4 (66.7) | 37 (31.0) | |
| Fibula | 1 (16.6) | 11 (8.6) | |
| Other | – | 10 (7.8) | |
| Chemotherapy regimen, n (%) | |||
| DIA | 5 (83.3) | 83 (70.7) | 1.00 |
| MMIA | 1 (16.7) | 27 (22.4) | |
| Other | – | 9 (6.9) | |
| Types of surgery, n (%) | |||
| Prosthesis | 3 (50.0) | 46 (38.3) | 0.51 |
| Biological reconstruction | 3 (50.0) | 73 (61.7) | |
| Response to chemotherapy, n (%) | |||
| Good | 4 (66.7) | 70 (58.6) | 0.65 |
| Poor | 2 (33.3) | 49 (41.4) | |
| Prosthetic loosening/fracture | 1 (16.7) | 8 (6.7) | 1.00 |
| Amputation | 3 (50.0) | 2 (1.7) | 0.00 |
| Recurrence | 1 (16.7) | 28 (23.5) | 1.00 |
| Metastasis | – | 59 (49.6) | 0.03 |
| Mortality | – | 65 (54.6) | 0.00 |
| Total | 6 (4.8) | 119 (95.2) | |
DIA, cisplatin-doxorubicin-ifosfamide chemotherapy regimen; MMIA, methotrexate-doxorubicin-ifosfamide chemotherapy regimen.